Phase 3 Clinical Trials With Primary Completion Dates in July 2020

This is a list of Phase 3 trials with primary completion dates in July 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
AMAGAMAG Pharmaceuticals, Inc.2020-07-01Phase 3NCT03893045A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
AMPEAmpio Pharmaceuticals, Inc.2020-07-01Phase 3NCT03988023Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.
AXSMAxsome Therapeutics, Inc.2020-07-01Phase 3NCT04039022Open-Label Safety Study of AXS-05 in Subjects With Depression
EXELExelixis, Inc.2020-07-01Phase 3NCT03690388A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy
MCRBSeres Therapeutics, Inc.2020-07-01Phase 3NCT03183128ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
MEDPMedpace Holdings, Inc.2020-07-01Phase 3NCT03464019Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
MISTMilestone Pharmaceuticals Inc.2020-07-01Phase 3NCT03464019Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
MYLMylan N.V.2020-07-01Phase 3NCT04344041COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
NKTRNektar Therapeutics2020-07-01Phase 3NCT02915744A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
OCGNOcugen, Inc.2020-07-01Phase 3NCT03591874Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
ONPHOncology Pharma Inc.2020-07-01Phase 3NCT02819960Prevention of Irinotecan Induced Diarrhea by Probiotics
OTLKOutlook Therapeutics, Inc.2020-07-01Phase 3NCT03844074A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
RTRXRetrophin, Inc.2020-07-01Phase 3NCT03041116Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Patients
VNDAVanda Pharmaceuticals Inc.2020-07-01Phase 3NCT04028492Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
VSTMVerastem, Inc.2020-07-01Phase 3NCT02049515A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
ZGNXZogenix, Inc.2020-07-01Phase 3NCT02826863A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
ZGNXZogenix, Inc.2020-07-01Phase 3NCT02682927A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome